

matter, comprising an anti-inflammatory effective amount of at least one peptide comprising the lysine-proline-valine tripeptide sequence, the proline moiety of which exists in its dextrorotatory optical isomer form (DPro), wherein said peptide comprises anti-inflammatory activity, in a physiologically/pharmaceutically acceptable medium therefor and where the lysine and valine residues contained in said lysine-proline-valine tripeptide sequence [can] exist either in their levorotatory or dextrorotatory ^{optical isomer forms} ~~to delay, inhibit, or reduce~~ ^{to delay, inhibit, or reduce} inflammation.

Claim 5, line 4, change "end-terminal" to --N-terminal--.

Claim 16, line 1, change "A method" to --The method--.

Claim 17, line 1, change "A method" to --The method--.

Claim 18, line 1, change "A method" to --The method--.

Claim 19, line 1, change "a method" to --The method--.